Christian A.’s Post

Don't miss our interview with Sanjay Juneja, M.D. We're covering several important topics: 1. How to catch cancer much earlier to "live long and prosper!" 2. Why current diagnostics, including genomic testing, fall short of finding the best therapy for you. 3. How the SAGE Oncotest can help you to receive the most effective treatment. https://lnkd.in/g9AAuH8v

📣 For ESMO members: Breaking Science in #GastrointestinalCancers. Michel P. Ducreux presents his findings on Sequences of regorafenib and trifluridine/tipiracil after failure of standard therapies for mCRC. 👉 Explore this video and the entire series on OncologyPRO now. 🔗 https://ow.ly/guAY50SFi6l

As I reflect on the updates presented at The EBMT-European Hematology Association (EHA) 6th European CAR-T meeting, it is evident that we’ve only begun to scratch the surface of what’s possible with CAR (T) therapies.   My highlights: 💡 Our increasing understanding of the mechanisms of-CAR-T treatment toxicities, and the improved prophylactic and treatment strategies being utilised to manage these 💡 The progress being made with next-generation CAR-Ts using approaches such as genome editing, and the enormous potential they will bring 💡 The ever-expanding utility of CAR-T therapies, not only in haematological malignancies and solid tumours, but in a variety of other therapeutic areas – with particularly exciting advances being made in autoimmune diseases, and senescence & cellular regeneration Want to hear directly from the speakers on some these hot topics? Head to our event page https://lnkd.in/eGC94E-Q to find out more!   #CARTtherapy #CART24 #EBMT #EHA #vjhemonc

This Friday, November 3, from 12:40 - 1:40 PM, stop by the exhibit hall at the North American Cystic Fibrosis Conference to hear our Director of Research, Daniella Ishimaru, PhD, present her poster titled “First Generation Aerosolized Lipid Nanoparticle/mRNA Therapy Rescues CFTR Function in CF hBEs.” We look forward to sharing our research with you. Be sure to stop by Booth 804 before or after Dr. Ishimaru’s presentation to hear more about our CF Pipeline. Patients first—always. #cysticfibrosis #GeneticMedicine #NACFC

Interesting cases using 18F-FAPI-74 Nouzha WiNMI leader,Group Expert of WiN Global EANM_WE,Vp #WiN Global,#WiNMI,#WiN for peace,#WiN YG,#WiN Africa,#WiN IAEA,#WiN France,#WiN Europe,#AMMN ,#SNMMI,#PSNM,#AI,#Nuclear Medicine,#Oncology,#Molecular Imaging,#Myocardial imaging,#ASCO,#EANM,#EANM_WE,#EANM_WE, #WARMTH, #alpha Therapy, #beta Nuclear Medicine therapyVp,#Oncidium,#ESMIT,#SFMN,#UCLA,#EJNMMI,#Americanoncologyinstitute,#Urology,#Prostate cancer,#CEA,#INSTN,#Clinical Nuclear Medicine ,#Endocrinology,#Parathyroid

📢 ABSTRACTS | At #ASH23, our experts had the pleasure of exhibiting and meeting you at this 4-day congress. It was an opportunity to discuss about the latest insights from our real-world patient databases in the major hematological indications. On this occasion, we would like to share with you our two APLUSA abstracts which have been published online on the ASH website. 👉 Main Treatment Choices in the 2 First Lines of Therapy for Multiple Myeloma in Patients with High Risk Cytogenetics: Lesson from the Real World in the EU5 Countries and the USA (https://hubs.ly/Q02dyJX60) 👉 Impact of Ethnicity in Treatment Choice for Multiple Myeloma in the 3 First Lines of Therapy: Data from Observational Retrospective Real-World Study in the US (https://hubs.ly/Q02dyLLW0) Want more information about our solutions? Contact us! https://hubs.ly/Q02dyLL80

Our next interview in the “Meet the Editors-in-Chief” series is with Prof. Dr. Giorgio Minotti. Watch the interview here ▶ https://lnkd.in/ewPyzS4U #KargerPublishers #publishing #ExperienceKarger #blog #oncology

Lung nodules - not an uncommon source of angst amongst doctors & patients as one always wonders if it’s benign or malignant. The article highlights how common it is in Western Europe. I reckon it might be more common in Asia, given the highest prevalence of infections as well as nodule-mimics like granulomas. Something to consider as we advocate for more low-dose CT scans to screen for lung cancer. In the absence of blood tests and other biomarkers, there isn’t much more than can be done besides to watch and wait - if it’s of a small size, CT scans over a period of time help ascertain if further intervention is warranted. https://lnkd.in/g6yneMTa

🔬 Check out this research from Elizabeth R. Plimack, MD, MS, FASCO, and colleagues which analyzed #mutations and pathologic complete response in patients with #MIBC. 🧠 Learn More:

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar